Mesalamine with Folic Acid for Inflammatory Bowel Disease Treatment

Mesalamine Dosing Recommendations

• For mild to moderate active disease, oral mesalamine 2-4g daily is recommended as effective first-line therapy for patients with ulcerative colitis, according to the American Gastroenterological Association 1, 4
• For maintenance therapy, the lowest effective dose should be used (typically ≥2g/day) for patients with ulcerative colitis, as recommended by the American Gastroenterological Association 1
• Once daily adequate dosing is as effective as divided dose regimens for both induction and maintenance of remission in patients with ulcerative colitis, according to the American Gastroenterological Association 1
• For more severe disease, maximum higher doses should be used until remission is induced in patients with ulcerative colitis, as recommended by the American Gastroenterological Association 1

Formulation Selection and Special Considerations

• Combination therapy with topical mesalamine 1g daily plus oral mesalamine 2-4g daily is more effective than either treatment alone for patients with distal disease or proctitis, according to the European Crohn’s and Colitis Organisation 4, 5
• Topical formulation should be determined by extent of inflammation (suppositories for disease to recto-sigmoid junction, foam or liquid enemas for more proximal disease) for patients with distal disease or proctitis, as recommended by the European Crohn’s and Colitis Organisation 4, 5
• Mesalamine has limited benefit in Crohn's disease and is ineffective at doses <2g/day, according to the American Gastroenterological Association 2, 3
• Mesalamine is less effective for patients who have needed steroids to induce remission, as noted by the American Gastroenterological Association 2, 3
• For patients on methotrexate, folic acid 5mg once weekly, taken 3 days after methotrexate administration, may reduce side effects, according to the National Institute for Health and Care Excellence 2, 3
• In patients with proximal constipation and distal colitis, treat the constipation with stool bulking agents or laxatives, as recommended by the European Crohn’s and Colitis Organisation 4, 5
• For patients who fail to improve on combination therapy (oral mesalamine with topical mesalamine or corticosteroids), oral prednisolone 40mg daily may be required, according to the European Crohn’s and Colitis Organisation 4
• For chronic active steroid-dependent disease, consider immunosuppressive therapy with azathioprine or mercaptopurine rather than long-term mesalamine, as recommended by the American Gastroenterological Association 2, 3

Common Pitfalls to Avoid

• Using inadequate dosing (<2g/day) for maintenance therapy, as noted by the American Gastroenterological Association 1, 2
• Not considering combination therapy (topical plus oral) when response to monotherapy is suboptimal, according to the European Crohn’s and Colitis Organisation 4, 5
• Failing to treat proximal constipation in patients with distal disease, as recommended by the European Crohn’s and Colitis Organisation 4, 5
• Not supplementing with folic acid when using mesalamine with methotrexate or sulfasalazine, according to the National Institute for Health and Care Excellence 2